Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Takes Another Step Forward In MS, Files Lemtrada NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi is seeking a six-month priority review for the multiple sclerosis drug Lemtrada, positioning it for a potential launch by the end of the year. Meanwhile, FDA action on Aubagio is expected in June.


Related Content

Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution
Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate
Myelin Repair Foundation Teams With Academia To Find Therapies That Can Halt MS
Sanofi Sets Sights On Multiple Sclerosis Leadership
Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif
MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?
Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts